Loading clinical trials...
Loading clinical trials...
A Multi-centre, Double-blind, Parallel-group, Randomised, Placebo Controlled Phase II a Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Different Doses of Orally Administered BI 1467335 During a 12-week Treatment Period Compared to Placebo in Patients With Clinical Evidence of NASH.
Conditions
Interventions
BI 1467335
Placebo
Locations
44
United States
Southern California Research Center
Coronado, California, United States
University of California San Diego
La Jolla, California, United States
eStudySite
La Mesa, California, United States
National Research Institute
Los Angeles, California, United States
National Research Institute
Los Angeles, California, United States
Quest Clinical Research
San Francisco, California, United States
Start Date
June 6, 2017
Primary Completion Date
June 14, 2019
Completion Date
June 14, 2019
Last Updated
June 11, 2020
NCT07265544
NCT06819917
NCT07221227
NCT06218589
NCT04785937
NCT03190538
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions